As últimas notícias da Dr. Falk Pharma
Bem-vindo à nossa Sala de Imprensa que fornece as últimas notícias, comunicados de imprensa, anúncios de ensaios clínicos, eventos e muito mais da Dr. Falk Pharma.
Siga-nos no LinkedIn!
![](/fileadmin/FP_HQ/newsroom/20240720_HerbertFalk/07_04_HerbertFalk.jpg)
Em memória do nosso fundador
Faz hoje 100 anos que nasceu o Dr. Dr. Herbert Falk
Saber mais
![](/fileadmin/FP_HQ/newsroom/20240515_EASL2024/EASL_Congress_2024_-_Partner_logo__COLOUR_%404x.png)
EASL 2024
From 5-8 June 2024 in Milan - we look forward to seeing you (exhibition space E2)
Saber mais
![](/fileadmin/FP_HQ/newsroom/20230215_PR_Renexxion_Gastroparese/renexxion_teaser.jpg)
FDA clearance of IND application for naronapride
...to treat gastroparesis and subsequent expansion of ongoing phase 2b study to the US
Saber mais
![](/fileadmin/FP_HQ/newsroom/20230215_PR_Renexxion_Gastroparese/renexxion_teaser.jpg)
Advancing the development of naronapride...
...for patients with PPI-non-responsive symptomatic GERD as the second naronapride indication
Saber mais
![](/fileadmin/FP_HQ/newsroom/20230519_IBD-Day/ibd-day-teaser.jpg)
Hoje é o Dia Mundial da DII!
Teste os seus conhecimentos e saiba mais sobre a DII
Saber mais
![](/fileadmin/FP_HQ/newsroom/20230228_RareDiseaseDay/teaser_Rare-Disease-Day-2023.jpg)
Rare Disease Day
As the experts in digestive and metabolic medicine, our focus is also on rare diseases.
Saber mais
![](/fileadmin/FP_HQ/newsroom/20230217_LinkedIn_3000Follower/FP_3000Follower_SK.png)
3000 LinkedIn-Followers!
Thank you very much!
Together we know more. Together we do more.
Saber mais
![](/fileadmin/FP_HQ/newsroom/20230215_PR_Renexxion_Gastroparese/renexxion_teaser.jpg)
Initiation of Phase II Study of naronapride in patients with gastroparesis
Renexxion Ireland and Dr. Falk Pharma announce that the first patient has been treated
Saber mais
![](/fileadmin/FP_HQ/newsroom/20221214_NewWork/newsroom_teaser-img_newwork.jpg)
New Work in Freiburg
Pilot space to find out which elements & spaces work for us
Saber mais
![](/fileadmin/FP_HQ/newsroom/20221020_Takeda/Logo_Takeda.jpg)
Collaboration and Licensing Agreement with Takeda and Zedira
To Develop First-in-Class Celiac Disease Therapy
Saber mais
![Logo Zedira](/fileadmin/FP_HQ/newsroom/20220701_PR_Zedira-Falk_NAFLD/newsroom_teaser-img_zedira.jpg)
NAFLD: Phase 2a proof of concept study of ZED1227
Dr. Falk Pharma and Zedira announce trial start for the treatment of non-alcoholic fatty liver disease. First patient enrolled in April.
Saber mais
![](/fileadmin/FP_HQ/newsroom/20220603_EASL/newsroom_teaser-img_easl22.jpg)
International Liver Congress™ in London
We are proud to be a sponsor and look forward to seeing you in person on our booth no. 69 or online, 22-26 June 2022!
Saber mais
![](/fileadmin/FP_Portugal/Newsroom/newsroom_teaser-img_esophagus.jpg)
Digestive Disease Week® 2022
We look forward to 2 exciting presentations on day 4 of this year’s DDW!
Saber mais
![](/fileadmin/FP_HQ/newsroom/20220510_PR_EoE-Day/newsroom_teaser-img_eoe-day.jpg)
Have difficulty swallowing food?
Difficulty swallowing and pain while eating may be warning signs of eosinophilic esophagitis (EoE). The first EoE Day will be held on May 22, 2022.
Saber mais
![](/fileadmin/FP_HQ/newsroom/newsroom_teaser-img_default.jpg)
Resposta à crise da Ucrânia
A Dr. Falk Pharma apoia a APOTHEKER HELFEN e.V.
Saber mais
![](/fileadmin/FP_HQ/newsroom/20220224_PR_Gueterbahnhof/newsroom_teaser-img_new-hq.jpg)
O futuro começa aqui
Planos concluídos para o futuro Falk Campus em Freiburgo
Saber mais
![Prometheus Logo Prometheus Logo](/fileadmin/FP_HQ/newsroom/20220103_PR_Prometheus_PR600/newsroom_teaser-img_prometheus.jpg)
Together we advance PR600
Investigational New Drug Application for PR600 expected in 3Q 2022.
Saber mais